Research Progress of Target Related Toxicity of Anti-tumor Drugs

Abstract

Abstract: With the rapid development of medicinal chemistry, bioscience, molecular biology and molecular pharmacology, there are many anti-tumor drugs under research, coming into clinical trials or having been approved. With the discovery of disease-associated mutation sites and signaling pathways, therapeutic approaches to these mutations and signaling pathways have emerged, which is named targeted therapies. Targeted therapies are more accurate than conventional drugs with few side effects, good applicability, and high specificity. However, a series of toxicities associated with therapeutic targets have also emerged. According to the mechanism of action of drugs, this article has summarized the target related toxicity of anti-tumor drugs, and hopes to provide some ideas and suggestions for the safety evaluation of targeted therapy.

Key words: target, toxicity, antineoplastic agent

CLC Number:

R965

LI Hong-ying, YANG Cui-ping,, JIN Hong-tao,. Research Progress of Target Related Toxicity of Anti-tumor Drugs[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 152-157.

References

[1] Talwar V, Pradeep Babu k V, Raina S. An overall review of targeted therapy in solid cancers[J]. Current Medicine Research and Practice, 2017, 7(3): 99-105.
[2] Pauliah M, Zanganeh S, Erfanzadeh M, et al. Chapter 10-Tumor Targeted Therapy[M]//Mahmoudi M, Laurent S. Iron Oxide Nanoparticles for Biomedical Applications. Elsevier. 2018: 273-290.
[3] Aragon-ching J B, Trump D L. Targeted therapies in the treatment of urothelial cancers [J]. Urologic Oncology: Seminars and Original Investigations, 2017, 35(7): 465-472.
[4] Grunewald T, Ledermann J A. Targeted Therapies for Ovarian Cancer[J]. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017, 41(S C): 139-152.
[5] Ke X, Shen L. Molecular targeted therapy of cancer: The progress and future prospect[J]. Frontiers in Laboratory Medicine, 2017, 1(2): 69-75.
[6] Baas J M, Krens L L, Guchelaar H J, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: A systema-
tic review [J]. Cancer Treatment Reviews, 2012, 38(5): 505-514.
[7] Jatoi A, Green E M, Rowland K M, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147[J]. Oncology, 2009, 77(2): 120-123.
[8] Lurje G, Nagashima F, Zhang W, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab[J]. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, 14(23): 7884-7895.
[9] Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies [J]. Clinical cancer research : an official journal of the American Association for Cancer Research,2007,13(13): 3913-3921.
[10] Wheatley-price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, 26(14): 2350-2357.
[11] Klinghammer K, Knodler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2010, 16(1): 304-310.
[12] Perea S, Oppenheimer D, Amador M, et al. Genotypic bases of EGFR inhibitors pharmacological actions[J]. Journal of Clinical Oncology, 2004, 22(14):3005.
[13] Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2005, 23 (15): 3536-3544.
[14] Ding P N, Lord S J, Gebski V, et al. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer [J]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, 12(4): 633-643.
[15] Chu C-Y, Chen K-Y, Wen-Cheng Chang J, et al. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities[J]. J Formos Med Assoc, 2017, 116(6): 413-423.
[16] Chang L F, Karin M K. Chang L, Karin M. Mammalian MAP kinase signaling cascade[J]. Nature，2001, 410(6824):37-40.
[17] Choe C H, Mcarthur G A, Caro I, et al. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib[J]. American Journal of Ophthalmology, 2014, 158(4):831-837.
[18] Poulikakos P I, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF[J]. Nature, 2010, 464(7287):427.
[19] Heidorn S J, Carla M, Steven W, et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF[J]. Cell, 2010, 140(2):209.
[20] Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation[J]. The New England journal of medicine, 2011, 365(15): 1448-1449.
[21] Zimmer L, Vaubel J, Livingstone E, et al. Side effects of systemic oncological therapies in dermatology[J]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2012, 10(7): 475-486.
[22] Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma[J]. The Annals of pharmacotherapy, 2011, 45(11): 1399-1405.
[23] Antonuzzo L, DEL RE M, Barucca V, et al. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors[J]. Cancer Treat Rev, 2017, 57:28-35.
[24] Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy[J]. Transplantation, 2005, 79(4): 476-482.
[25] Houde V P, Brule S, Festuccia W T, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue[J]. Diabetes, 2010, 59(6): 1338-1348.
[26] Hardinger K L, Cornelius L A, Trulock E P, 3RD, et al. Sirolimus-
induced leukocytoclastic vasculitis[J]. Transplantation, 2002, 74(5): 739-743.
[27] Antonuzzo L, Del R M, Barucca V, et al. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors[J]. Cancer Treatment Reviews, 2017, 57:28.
[28] Pallet N, Legendre C. Adverse events associated with mTOR inhibitors[J]. Expert opinion on drug safety, 2013, 12(2): 177-186.
[29] Kim J E, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis [J]. Diabetes, 2004, 53(11): 2748-2756.
[30] Thaunat O, Beaumont C, Lechaton S, et al. Late introduction of sirolimus induces anemia in renal transplant recipients[J]. Transplantation, 2007, 83(9): 1283.
[31] Feagans J, Victor D, Moehlen M, et al. Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity[J]. The Journal of the Louisiana State Medical Society: official organ of the Louisiana State Medical Society, 2009, 161(3): 166, 168-172.
[32] Schonenberger E, Ehrich J H, Haller H, et al. The podocyte as a direct target of immunosuppressive agents [J]. Nephr-ology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, 26(1): 18-24.
[33] Timokhina I, Kissel H, Stella G, et al. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation[J]. The EMBO journal, 1998, 17(21): 6250-6262.
[34] Li W, Fu J, Zhang S, et al. The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis[J]. Toxicology and applied pharmacology, 2015, 285(2): 98-109.
[35] 方罗, 吴盈盈, 张翀，等. 近5年全球抗肿瘤药物研发现状(Ⅰ) [J]. 中国肿瘤, 2013, 22(7): 562-569.
[36] Bhagavath A, Geyer A. Carfilzomib Pulmonary Toxicity[J]. Chest, 2016, 150(4, S): 492A.
[37] Bernardini A, Ponticelli E. Management of Toxicities Associated with Carfilzomib: an Update of the Italian Experience[J]. Clinical Lymphoma Myeloma & Leukemia, 2015, 15:e319-e320.
[38] Dugbartey G J, Peppone L J, DE Graaf I A. An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures[J]. Toxicology, 2016, 371：58-66.
[39] Wilmes A, Bielow C, Ranninger C, et al. Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcripto-mics, proteomics, metabolomics and biokinetics[J]. Toxicology in vitro: an international journal published in association with BIBRA, 2015, 30(1 Pt A): 117-127.
[40] Seavey M M, Dobrzanski P. The many faces of Janus kinase[J]. Biochemical pharmacology, 2012, 83(9): 1136-1145.
[41] Gunerka P, Dymek B, Stanczak A, et al. Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors[J]. European journal of pharmacology, 2015, 765:188-197.
[42] Shreberk-hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review[J]. Journal of the American Academy of Dermatology, 2017, 76(4): 745-753.
[43] 张媛, 程雨兰, 周金培，等. 以c-Met为肿瘤治疗靶点的受体酪氨酸激酶抑制剂的研究进展[J]. 中国药科大学学报, 2015, 46（1): 16-27.
[44] Tridente G. Chapter 16-Crizotinib[M]. Adverse Events and Oncotargeted Kinase Inhibitors. Academic Press, 2017: 353-374.
[45] Cr quit P, Wislez m, fleury feith J, et al. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review[J]. Journal of Thoracic Oncology, 2015, 10(8): 1148-1155.
[46] Scagliotti G V, Novello S, Schiller J H, et al. Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer[J]. Clinical Lung Cancer, 2012, 13(5): 391-395.
[47] 蒋涛, 周彩存. HGF/c-MET抑制剂治疗非小细胞肺癌的研究进展[J]. 中国肺癌杂志, 2015, 18(4):240-244.
[48] Wu Y L, Yang C H, Kim D W, et al. Safety and efficacy of inc280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), met-positive NSCLC: A single-arm phase lb/ll study[EB/OL].（2014-06-03）[2017-12-25].https://meetinglibrary.asco.org/record/92544/abstract.
[49] 程远, 黎军和. PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展[J]. 中国肿瘤临床, 2015, 37(24):1178-1182.
[50] 黄乐富, 邸岩, 徐小寒，等. PD-1/PD-L1阻断剂免疫治疗不良反应及其处理原则 [J]. 中国药物应用与监测, 2017, 14(3): 177-182.
[51] Kao J C, Liao B, Markovic S N, et al. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies[J]. JAMA neurology, 2017, 74(10): 1216-1222.
[52] williams T J, Benavides D R, Patrice K A, et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer[J]. JAMA neurology, 2016, 73(8): 928-933.
[53] Belkhir R, Burel S L, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment[J]. Annals of the rheumatic diseases, 2017, 76(10): 1747-1750.
[54] Bonifant C L, Jackson H J, Brentjens R J, et al. Toxicity and management in CAR T-cell therapy[J]. Molecular Therapy Oncolytics, 2016, 3:16011.
[55] Maude S L, Frey N, Shaw P A, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. The New England journal of medicine, 2014, 371(16): 1507-1517.
[56] Lee D W, Gardner R, Porter D L, et al. Current concepts in the diagnosis and management of cytokine release syndrome[J]. Blood, 2014, 124(2):188.
[57] Davila M L, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Science Translational Medicine, 2014, 6(224):224ra25.
[58] Lee D W, Kochenderfer J N, Stetler-stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967):517.
[59] Lamers C H, Sleijfer S, Vulto A G, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2006, 24(13): 20-22.
[60] Lamers C H, Sleijfer S, Van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity[J]. Molecular therapy : the journal of the American Society of Gene Therapy, 2013, 21(4): 904-912.
[61] Kershaw M H, Westwood J A, Parker L L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J]. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, 12(20 Pt 1): 6106-6115.